ILTOO Pharma SAS today announced the publication of a peer-reviewed manuscript titled, “Low-dose interleukin-2 in patients with bipolar depression: a phase 2 randomised double-blind placebo-controlled trial” in the journal Brain, Behavior, and Immunity.